SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Aguayo, A. Articles by Albitar, M. Search for Related Content PubMed PubMed Citation Articles by Aguayo, A. Articles by Albitar, M. Related Collections Hemostasis, Thrombosis, and Vascular Biology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2000, Vol. 96, No. 6, pp. 2240-2245 NEOPLASIA Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Alvaro Aguayo, Hagop Kantarjian, Taghi Manshouri, Cristi Gidel, Elihu Estey, Deborah Thomas, Charles Koller, Zeev Estrov, Susan O'Brien, Michael Keating, Emil Freireich, and Maher Albitar From the Departments of Leukemia, Hematopathology, and Bioimmunotherapy, University of Texas, M. D. Anderson Cancer Center, Houston, TX. Angiogenesis has been associated with the growth, dissemination, and metastasis of solid tumors. The aims of this study were to evaluate the vascularity and the levels of angiogenic factors in patients with acute and chronic leukemias and myelodysplastic syndromes (MDS). The numbers of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), tumor necrosis growth factor- (TNF-), tumor growth factor- (TGF-), and hepatocyte growth factor (HGF) were determined in 417 plasma samples. Except for chronic lymphocytic leukemia (CLL), vascularity was significantly higher in all leukemias and MDS compared with control bone marrows. The highest number of blood vessels and largest vascular area were found in chronic myeloid leukemia (CML). VEGF, bFGF, and HGF plasma levels were significantly increased in acute myeloid leukemia (AML), CML, CLL, chronic myelomonocytic leukemia (CMML), and MDS. HGF, TNF-, and bFGF but not VEGF were significantly increased in acute lymphoblastic leukemia (ALL). TNF- levels were significantly increased in all diseases except for AML and MDS. No significant increase was found in TGF- in any leukemia or MDS. The highest plasma levels of VEGF were in CML, and the highest plasma levels of bFGF were in CLL. The levels of HGF were highest in CMML. These data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in the leukemogenic process. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. H. Kim, W. Xu, S. Kamel-Reid, X. Liu, C. W. Jung, S. Kim, and J. H. Lipton Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy Ann. Onc., October 29, 2009; (2009) mdp452v1. [Abstract] [Full Text] [PDF] T. T.-F. Shih, H.-A. Hou, C.-Y. Liu, B.-B. Chen, J.-L. Tang, H.-Y. Chen, S.-Y. Wei, M. Yao, S.-Y. Huang, W.-C. Chou, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival Blood, April 2, 2009; 113(14): 3161 - 3167. [Abstract] [Full Text] [PDF] L. Zhou, A. N. Nguyen, D. Sohal, J. Ying Ma, P. Pahanish, K. Gundabolu, J. Hayman, A. Chubak, Y. Mo, T. D. Bhagat, et al. Inhibition of the TGF-{beta} receptor I kinase promotes hematopoiesis in MDS Blood, October 15, 2008; 112(8): 3434 - 3443. [Abstract] [Full Text] [PDF] S. Monteghirfo, F. Tosetti, C. Ambrosini, S. Stigliani, S. Pozzi, F. Frassoni, G. Fassina, S. Soverini, A. Albini, and N. Ferrari Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-{kappa}B and p53 modulation Mol. Cancer Ther., September 1, 2008; 7(9): 2692 - 2702. [Abstract] [Full Text] [PDF] P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood, September 1, 2008; 112(5): 2139 - 2148. [Abstract] [Full Text] [PDF] I. Petit, M. A. Karajannis, L. Vincent, L. Young, J. Butler, A. T. Hooper, K. Shido, H. Steller, D. J. Chaplin, E. Feldman, et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood, February 15, 2008; 111(4): 1951 - 1961. [Abstract] [Full Text] [PDF] S. Pillozzi, M. F. Brizzi, P. A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, V. Boddi, L. Pegoraro, A. Becchetti, and A. Arcangeli VEGFR-1 (FLT-1), {beta}1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome Blood, August 15, 2007; 110(4): 1238 - 1250. [Abstract] [Full Text] [PDF] M. Melchert and A. F. List Management of RBC-Transfusion Dependence Hematology, January 1, 2007; 2007(1): 398 - 404. [Abstract] [Full Text] [PDF] T. A. Navas, M. Mohindru, M. Estes, J. Y. Ma, L. Sokol, P. Pahanish, S. Parmar, E. Haghnazari, L. Zhou, R. Collins, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors Blood, December 15, 2006; 108(13): 4170 - 4177. [Abstract] [Full Text] [PDF] I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962 Clin. Cancer Res., December 1, 2006; 12(23): 6978 - 6984. [Abstract] [Full Text] [PDF] L. Matuszewski, T. Persigehl, A. Wall, N. Meier, R. Bieker, H. Kooijman, B. Tombach, R. Mesters, W. E. Berdel, W. Heindel, et al. Assessment of Bone Marrow Angiogenesis in Patients with Acute Myeloid Leukemia by Using Contrast-enhanced MR Imaging with Clinically Approved Iron Oxides: Initial Experience Radiology, December 1, 2006; 242(1): 217 - 224. [Abstract] [Full Text] [PDF] J. Redondo-Munoz, E. Escobar-Diaz, R. Samaniego, M. J. Terol, J. A. Garcia-Marco, and A. Garcia-Pardo MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by {alpha}4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration Blood, November 1, 2006; 108(9): 3143 - 3151. [Abstract] [Full Text] [PDF] S. Shalapour, A. Zelmer, M. Pfau, E. Moderegger, C. Costa-Blechschmidt, F. K.H. van Landeghem, T. Taube, I. Fichtner, C. Buhrer, G. Henze, et al. The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo. Clin. Cancer Res., September 15, 2006; 12(18): 5526 - 5532. [Abstract] [Full Text] [PDF] M. Stefanidakis and E. Koivunen Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression Blood, September 1, 2006; 108(5): 1441 - 1450. [Abstract] [Full Text] [PDF] A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF] R. Fragoso, T. Pereira, Y. Wu, Z. Zhu, J. Cabecadas, and S. Dias VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease Blood, February 15, 2006; 107(4): 1608 - 1616. [Abstract] [Full Text] [PDF] W. Liu, M. Guo, Y.-B. Xu, D. Li, Z.-N. Zhou, Y.-L. Wu, Z. Chen, S. C. Kogan, and G.-Q. Chen Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia Blood, January 15, 2006; 107(2): 698 - 707. [Abstract] [Full Text] [PDF] W. Fureder, M.-T. Krauth, W. R. Sperr, K. Sonneck, I. Simonitsch-Klupp, L. Mullauer, M. Willmann, H.-P. Horny, and P. Valent Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia Am. J. Pathol., January 1, 2006; 168(1): 123 - 130. [Abstract] [Full Text] [PDF] J. S. Carew, S. T. Nawrocki, Y. V. Krupnik, K. Dunner Jr, D. J. McConkey, M. J. Keating, and P. Huang Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL Blood, January 1, 2006; 107(1): 222 - 231. [Abstract] [Full Text] [PDF] S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia Blood, December 15, 2005; 106(13): 4303 - 4307. [Abstract] [Full Text] [PDF] P. O. Iversen and H. Wiig Tumor Necrosis Factor {alpha} and Adiponectin in Bone Marrow Interstitial Fluid from Patients with Acute Myeloid Leukemia Inhibit Normal Hematopoiesis Clin. Cancer Res., October 1, 2005; 11(19): 6793 - 6799. [Abstract] [Full Text] [PDF] K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al. Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies Clin. Cancer Res., September 15, 2005; 11(18): 6615 - 6624. [Abstract] [Full Text] [PDF] M. Chavez-MacGregor, A. Aviles-Salas, D. Green, A. Fuentes-Alburo, C. Gomez-Ruiz, and A. Aguayo Angiogenesis in the Bone Marrow of Patients with Breast Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5396 - 5400. [Abstract] [Full Text] [PDF] M. Ito, Y. Sakai, M. Furumoto, H. Segawa, S. Haito, S. Yamanaka, R. Nakamura, M. Kuwahata, and K.-i. Miyamoto Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1101 - E1109. [Abstract] [Full Text] [PDF] D. Ferguson, L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models Clin. Cancer Res., April 15, 2005; 11(8): 3045 - 3054. [Abstract] [Full Text] [PDF] S. Loges, G. Heil, M. Bruweleit, V. Schoder, M. Butzal, U. Fischer, U. M. Gehling, G. Schuch, D. K. Hossfeld, and W. Fiedler Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival J. Clin. Oncol., February 20, 2005; 23(6): 1109 - 1117. [Abstract] [Full Text] [PDF] G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF] K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF] S. Kumar, T. E. Witzig, M. Timm, J. Haug, L. Wellik, T. K. Kimlinger, P. R. Greipp, and S. V. Rajkumar Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression Blood, August 15, 2004; 104(4): 1159 - 1165. [Abstract] [Full Text] [PDF] J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al. Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab Clin. Cancer Res., June 1, 2004; 10(11): 3577 - 3585. [Abstract] [Full Text] [PDF] H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF] H. M. Kvasnicka, J. Thiele, P. Staib, A. Schmitt-Graeff, M. Griesshammer, J. Klose, K. Engels, and S. Kriener Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy Blood, May 1, 2004; 103(9): 3549 - 3551. [Abstract] [Full Text] [PDF] R. Kurzrock, M. Albitar, J. E. Cortes, E. H. Estey, S. H. Faderl, G. Garcia-Manero, D. A. Thomas, F. J. Giles, M. E. Ryback, A. Thibault, et al. Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome J. Clin. Oncol., April 1, 2004; 22(7): 1287 - 1292. [Abstract] [Full Text] [PDF] A. Ruddell, P. Mezquita, K. A. Brandvold, A. Farr, and B. M. Iritani B Lymphocyte-Specific c-Myc Expression Stimulates Early and Functional Expansion of the Vasculature and Lymphatics during Lymphomagenesis Am. J. Pathol., December 1, 2003; 163(6): 2233 - 2245. [Abstract] [Full Text] R. Bieker, T. Padro, J. Kramer, M. Steins, T. Kessler, S. Retzlaff, F. Herrera, J. Kienast, W. E. Berdel, and R. M. Mesters Overexpression of Basic Fibroblast Growth Factor and Autocrine Stimulation in Acute Myeloid Leukemia Cancer Res., November 1, 2003; 63(21): 7241 - 7246. [Abstract] [Full Text] [PDF] S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease PNAS, September 30, 2003; 100(20): 11630 - 11635. [Abstract] [Full Text] [PDF] F. J. Giles, A. T. Stopeck, L. R. Silverman, J. E. Lancet, M. A. Cooper, A. L. Hannah, J. M. Cherrington, A.-M. O'Farrell, H. A. Yuen, S. G. Louie, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood, August 1, 2003; 102(3): 795 - 801. [Abstract] [Full Text] [PDF] M. Rumpel, T. Friedrich, and M. W. N. Deininger Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase Blood, June 1, 2003; 101(11): 4641 - 4643. [Full Text] [PDF] M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler Signal transducer and activator of transcription proteins in leukemias Blood, April 15, 2003; 101(8): 2940 - 2954. [Abstract] [Full Text] [PDF] J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, A. Thibault, W. Rackoff, C. Koller, S. O'Brien, G. Garcia-Manero, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood, March 1, 2003; 101(5): 1692 - 1697. [Abstract] [Full Text] [PDF] S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, L. Wellik, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma Blood, March 1, 2003; 101(5): 1715 - 1717. [Abstract] [Full Text] [PDF] J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial Clin. Cancer Res., January 1, 2003; 9(1): 307 - 315. [Abstract] [Full Text] [PDF] G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF] G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo Blood, December 15, 2002; 100(13): 4622 - 4628. [Abstract] [Full Text] [PDF] J. M.L. Ebos, J. Tran, Z. Master, D. Dumont, J. V. Melo, E. Buchdunger, and R. S. Kerbel Imatinib Mesylate (STI-571) Reduces Bcr-Abl-Mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia Mol. Cancer Res., December 1, 2002; 1(2): 89 - 95. [Abstract] [Full Text] [PDF] M. Mayerhofer, P. Valent, W. R. Sperr, J. D. Griffin, and C. Sillaber BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin Blood, November 15, 2002; 100(10): 3767 - 3775. [Abstract] [Full Text] [PDF] S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood, October 16, 2002; 100(9): 3344 - 3351. [Abstract] [Full Text] [PDF] R. S. Go, A. L. Horstman, K. Neben, and H. Goldschmidt Correspondence re: K. Neben et al., High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res., 7: 2675-2681, 2001. Clin. Cancer Res., August 1, 2002; 8(8): 2750 - 2751. [Full Text] [PDF] L. M. Rimsza, K. P. Ahrens, J. K. Massey, K. M. Pastos, M. G. Mainwaring, and R. C. Braylan AML, angiogenesis, and prognostic variables Blood, July 30, 2002; 100(4): 1517 - 1518. [Full Text] [PDF] M. Albitar, T. Manshouri, Y. Shen, D. Liu, M. Beran, H. M. Kantarjian, A. Rogers, I. Jilani, C. W. Lin, S. Pierce, et al. Myelodysplastic syndrome is not merely "preleukemia" Blood, July 18, 2002; 100(3): 791 - 798. [Abstract] [Full Text] [PDF] S. V. Rajkumar, R. A. Mesa, R. Fonseca, G. Schroeder, M. F. Plevak, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig, M. A. Gertz, et al. Bone Marrow Angiogenesis in 400 Patients with Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, and Primary Amyloidosis Clin. Cancer Res., July 1, 2002; 8(7): 2210 - 2216. [Abstract] [Full Text] [PDF] R. A. Mesa, C. A. Hanson, C.-Y. Li, S.-Y. Yoon, S. V. Rajkumar, G. Schroeder, and A. Tefferi Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia Blood, May 13, 2002; 99(11): 4131 - 4137. [Abstract] [Full Text] [PDF] F. Wimazal, J.-H. Jordan, W. R. Sperr, A. Chott, S. Dabbass, K. Lechner, H. P. Horny, and P. Valent Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis Am. J. Pathol., May 1, 2002; 160(5): 1639 - 1645. [Abstract] [Full Text] [PDF] M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells Blood, May 1, 2002; 99(9): 3383 - 3389. [Abstract] [Full Text] [PDF] S. Dias, S. V. Shmelkov, G. Lam, and S. Rafii VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition Blood, April 1, 2002; 99(7): 2532 - 2540. [Abstract] [Full Text] [PDF] M. Rusnati, C. Urbinati, E. Tanghetti, P. Dell'Era, H. Lortat-Jacob, and M. Presta Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2 PNAS, March 21, 2002; (2002) 72651899. [Abstract] [Full Text] [PDF] S. Dias, M. Choy, K. Alitalo, and S. Rafii Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy Blood, March 15, 2002; 99(6): 2179 - 2184. [Abstract] [Full Text] [PDF] S. Verstovsek, H. Kantarjian, T. Manshouri, J. Cortes, F. J. Giles, A. Rogers, and M. Albitar Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia Blood, March 15, 2002; 99(6): 2265 - 2267. [Abstract] [Full Text] [PDF] M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood, February 1, 2002; 99(3): 834 - 839. [Abstract] [Full Text] [PDF] F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text] B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text] A. Rosenwald, A. A. Alizadeh, G. Widhopf, R. Simon, R. E. Davis, X. Yu, L. Yang, O. K. Pickeral, L. Z. Rassenti, J. Powell, et al. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia J. Exp. Med., December 3, 2001; 194(11): 1639 - 1648. [Abstract] [Full Text] [PDF] J. L. Gabrilove Hematologic Malignancies: An Opportunity for Targeted Drug Therapy Oncologist, October 1, 2001; 6(2008): 1 - 3. [Full Text] [PDF] A. F. List Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 24 - 31. [Abstract] [Full Text] [PDF] F. J. Giles The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 32 - 39. [Abstract] [Full Text] [PDF] S. Dias, K. Hattori, B. Heissig, Z. Zhu, Y. Wu, L. Witte, D. J. Hicklin, M. Tateno, P. Bohlen, M. A. S. Moore, et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias PNAS, September 11, 2001; 98(19): 10857 - 10862. [Abstract] [Full Text] [PDF] L. Sun, M. Vitolo, and A. Passaniti Runt-related Gene 2 in Endothelial Cells: Inducible Expression and Specific Regulation of Cell Migration and Invasion Cancer Res., July 1, 2001; 61(13): 4994 - 5001. [Abstract] [Full Text] [PDF] A. R. Kini, L. C. Peterson, M. S. Tallman, and M. W. Lingen Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid Blood, June 15, 2001; 97(12): 3919 - 3924. [Abstract] [Full Text] [PDF] P. Rameshwar, D. D. Joshi, P. Yadav, J. Qian, P. Gascon, V. T. Chang, D. Anjaria, J. S. Harrison, and X. Song Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis Blood, May 15, 2001; 97(10): 3025 - 3031. [Abstract] [Full Text] [PDF] A. Ferrajoli, T. Manshouri, Z. Estrov, M. J. Keating, S. O’Brien, S. Lerner, M. Beran, H. M. Kantarjian, E. J. Freireich, and M. Albitar High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia Clin. Cancer Res., April 1, 2001; 7(4): 795 - 799. [Abstract] [Full Text] R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF] M. Rusnati, C. Urbinati, E. Tanghetti, P. Dell'Era, H. Lortat-Jacob, and M. Presta Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2 PNAS, April 2, 2002; 99(7): 4367 - 4372. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020